Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Curie-Cancer and Biolog-id Sign Partnership Agreement

Published: Wednesday, June 05, 2013
Last Updated: Wednesday, June 05, 2013
Bookmark and Share
Within the partnership, Curie-Cancer and Biolog-id will develop a pilot system of RFID tags suitable for use in tracking cancer chemotherapy preparations.

Curie-Cancer and Biolog-id have announced a partnership to develop an RFID (Radio Frequency Identification) solution for use in tracking chemotherapy bags.

The collaboration aims to make it possible to comprehensively track chemotherapy preparations through the whole process, from centralized pharmacy preparation through to administration to patients in health care settings.

Within a multi-site hospital setting like the Institut Curie, the drug circuit is a structured process involving multiple functions.

The larger the number of steps (prescribing, preparing, dispensing and administering), clinical stakeholders (doctors, pharmacists, pharmacy technicians and nurses) and information and product flows, the more complex the process and the greater the potential for error.

Administering one particular patient's chemotherapy preparation to another patient may have tragic consequences, but it is incredibly rare.

A more common occurrence, however, is that a preparation intended for one health care department is routed to another.

The considerable cost of some cancer drugs and the disruption to activity within the department mean that this can have significant consequences.

Against a background of cost control and safety and quality in health care it is crucial for any technological response to reflect standard practice.

With extensive experience in the field of blood bag traceability, Biolog-id intends to apply its expertise to the monitoring and tracking of chemotherapy bags.

Based on a label that incorporates an electronic RFID tag and is affixed to every preparation, this innovation represents a technological breakthrough: tag information is updated automatically at different stages of the process (preparation, transportation and administration).

Preparations therefore become 'intelligent', offering the scope for storage of additional information, such as drug dosage, patient identity, stages in manufacture and inspection and routing.

The concept also aims to improve safety in health care over time by guaranteeing complete traceability for all unit dose preparations dispensed for a named individual, including parenteral nutrition, dialysis bags and other injectable preparations.

Biolog-id was therefore looking for a hospital facility with an interest in developing this type of solution and with the capacity for testing and allocating health care staff time to provide the clinical expertise required.

"We were interested in this idea right from the start," said Marion Lafay-Bourquin, pharmacist, and Christian Magne, manager within the Pharmacy department. "Over time one of the potential applications for this technology is in tracking preparations shared by the Institut Curie's different hospital sites."

The project involves over a dozen people, with the initial aim of defining the technical specifications for Biolog-id's proposed traceability solution in conjunction with medical staff, then testing it in parallel with the existing system.

Biolog-id's goal is to verify the pilot solution in place at the Institut Curie, then make it available to other institutions in France and worldwide.

"As an SME, it is not always easy to access academic expertise. However, to stay competitive, it is something we have to do," said Jean-Claude Mongrenier, chairman and CEO of Biolog-id.

Mongrenier continued, "There was an immediate rapport with Curie-Cancer, because they, like us, were aiming to improve the safety of patient care and reduce costs. In addition, they had a clear desire to help an SME and to support us in developing our plans, which we definitely appreciated."

"We are delighted to be able to contribute to the development of a French SME like Biolog-id," said Damien Salauze, director of Curie-Cancer "This is the essence of the Institut Carnot label which we were awarded by the French government in 2011 in recognition of our drive to provide concrete solutions for industry and ultimately for patients. Our partnerships usually involve a significant element of laboratory-based research work, but I am delighted that our expertise in hospital settings also addresses the requirements of other types of industrial partner."


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More Than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Curie-Cancer and DNA Therapeutics Partner in the Fight Against Cancers
Their clinical and translational research program has developed Dbait molecules now in Phase I clinical trial in patients with advanced melanoma.
Thursday, March 06, 2014
Curie-Cancer and Servier Continue a Renewed Partnership in Cancer Research
Their joint aim is to identify new therapeutic targets in ‘triple negative’ breast cancers.
Wednesday, January 29, 2014
Curie-Cancer and Sanofi Cooperate in Research on Ovarian Cancer
Preclinical program of translational research tasked with identifying new target proteins.
Wednesday, June 19, 2013
Curie-Cancer and Roche Strengthen Partnership
Curie-Cancer and Roche build on four years partnership by increasing translational research programs, speeding up development of new cancer treatments.
Friday, May 17, 2013
Curie-Cancer and Vygon Sign a Partnership Agreement Extension
The Curie-Cancer and Vygon partnership will extend over several years and will achieve the development of catheters and implantable ports with increased resistance to nosocomial infections, for launch on the international market.
Tuesday, April 16, 2013
Curie-Cancer and GenoSplice Technology Sign Bioinformatics Partnership Agreement
The innovative partnership is planned to run for several years to develop unique, high value added genomic approaches.
Wednesday, January 30, 2013
Curie-Cancer Funds its First Selection of Five Late-Stage Projects
Funding of these first five projects enables Institut Curie’s discoveries to progress more rapidly to the industrial stage, making innovation available to patients more quickly.
Friday, December 14, 2012
Scientific News
How Skeletal Stem Cells Form The Blueprint Of The Face
USC researchers discover that two types of molecular signals work to control where and when stem cells turn into facial cartilage.
Intestinal Worms Boost Immune System In A Surprising Way
EPFL researchers find that intestinal worm infections cause lymph nodes to produce more immune cells as well as grow in size.
Measuring The Airborne Toxicants Urban Bicyclists Inhale
Researchers analyze breath biomarkers to measure uptake of volatile organic compounds by bicyclists.
Breast Milk Hormones Impact Bacteria In Infants’ Guts
Intestinal microbiome of children born to obese mothers significantly different from those born to mothers of healthy weight, CU Anschutz researchers find.
Newborn Screening Test Developed For Rare, Deadly Neurological Disorder
Scientists have developed a new dried blood spot screening test for Niemann-Pick type C, with goal to speed diagnosis and treatment.
'Kidney on a Chip' Facilitates Safer Drug Dosing
University of Michigan researchers have used a "kidney on a chip" device to mimic the flow of medication through human kidneys and measure its effect on kidney cells.
New Autism Blood Biomarker Identified
Researchers at UT Southwestern Medical Center have identified a blood biomarker that may aid in earlier diagnosis of children with autism spectrum disorder, or ASD.
New Method Allows First Look At Embryo Implantation
Researchers at The Rockefeller University develop a method that shows the molecular and cellular processes that occur up to day 14 after fertilization.
Ketamine Metabolism Lifts Depression
NIH-funded team finds rapid-acting, non-addicting agent in mouse study.
Faster, Cheaper Way to Produce New Antibiotics
A novel way of synthesising a promising new antibiotic has been identified by scientists at the University of Bristol.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!